Companies and individuals in North America brace for US President Donald Trump's potential 25% tariffs on Canadian and ...
The US Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.
Trump's tariffs threaten to blow up the trade agreement he himself negotiated with America's neighbours in his first term.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback